Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La RochefiledCriticalHoffmann La Roche
Publication of UY23428A1publicationCriticalpatent/UY23428A1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions
(AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Abstract
La presente invención se refiere a un procedimiento para la obtención de compuestos de formula I (figura 1) en donde R4 significa heterociclilo, entre otras posibilidades; R5 significa heterociclilmetilo, entre otras posibilidades. Como ejemplo no limitante: p-t-butil-N-[6-(2-hidroxietoxi)-5-(o-metoxifenoxi)-4-pirimidinil]bencenosulfonamida. Pueden ser utilizadas como ingredientes activos para la elaboración de medicamentos para el tratamiento de trastornos circulatorios, especialmente hipertensión, isquemia, vasospasmo y angina pectoris.The present invention refers to a process for obtaining compounds of formula I (figure 1) in which R4 represents heterocyclyl, among other possibilities; R5 signifies heterocyclylmethyl, among other possibilities. As a non-limiting example: p-t-butyl-N- [6- (2-hydroxyethoxy) -5- (o-methoxyphenoxy) -4-pyrimidinyl] benzenesulfonamide. They can be used as active ingredients for the manufacture of drugs for the treatment of circulatory disorders, especially hypertension, ischemia, vasospasm and angina pectoris.
UY23428A1991-06-131992-06-12
PROCEDURE FOR THE PREPARATION OF NEW SULFONAMIDES
UY23428A1
(en)
DERIVATIVE OF GUANAIDINA N- [CARBONIL (HETEROARIL-SUBSTITUTED FOR 5 MEMBERS)], A NA + / H + INTERCHANGER INHIBITOR THAT INCLUDES SUCH A DERIVATIVE AND USES IN THE MANUFACTURE OF MEDICINES.